Covalon Technologies Past Earnings Performance
Past criteria checks 0/6
Covalon Technologies has been growing earnings at an average annual rate of 1.3%, while the Biotechs industry saw earnings growing at 13.8% annually. Revenues have been declining at an average rate of 8.1% per year.
Key information
1.3%
Earnings growth rate
3.4%
EPS growth rate
Biotechs Industry Growth | 51.1% |
Revenue growth rate | -8.1% |
Return on equity | -27.9% |
Net Margin | -19.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Covalon Technologies Ltd.'s (CVE:COV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Feb 17Insufficient Growth At Covalon Technologies Ltd. (CVE:COV) Hampers Share Price
Dec 22We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth
Sep 02We Think Covalon Technologies (CVE:COV) Needs To Drive Business Growth Carefully
May 26Is Covalon Technologies (CVE:COV) Using Too Much Debt?
Apr 29Covalon Technologies (CVE:COV) Is Making Moderate Use Of Debt
Dec 29Revenue & Expenses BreakdownBeta
How Covalon Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 25 | -5 | 18 | 1 |
30 Sep 23 | 27 | -4 | 17 | 1 |
30 Jun 23 | 25 | -6 | 17 | 1 |
31 Mar 23 | 23 | -7 | 17 | 1 |
31 Dec 22 | 19 | -9 | 16 | 1 |
30 Sep 22 | 18 | -9 | 15 | 1 |
30 Jun 22 | 19 | -4 | 11 | 1 |
31 Mar 22 | 21 | -2 | 10 | 1 |
31 Dec 21 | 22 | 0 | 9 | 1 |
30 Sep 21 | 20 | 0 | 8 | 1 |
30 Jun 21 | 7 | -4 | 2 | 1 |
31 Mar 21 | 7 | -4 | 3 | 1 |
31 Dec 20 | 8 | -8 | 7 | 1 |
30 Sep 20 | 14 | -8 | 11 | 1 |
30 Jun 20 | 26 | -8 | 23 | 1 |
31 Mar 20 | 27 | -12 | 26 | 1 |
31 Dec 19 | 35 | -8 | 28 | 1 |
30 Sep 19 | 34 | -9 | 29 | 1 |
30 Jun 19 | 34 | -6 | 26 | 1 |
31 Mar 19 | 35 | -1 | 23 | 1 |
31 Dec 18 | 28 | -1 | 19 | 1 |
30 Sep 18 | 27 | 2 | 17 | 1 |
30 Jun 18 | 30 | 3 | 19 | 1 |
31 Mar 18 | 28 | 1 | 19 | 1 |
31 Dec 17 | 28 | 2 | 18 | 1 |
30 Sep 17 | 27 | 2 | 18 | 1 |
30 Jun 17 | 18 | -1 | 14 | 1 |
31 Mar 17 | 15 | -1 | 12 | 1 |
31 Dec 16 | 10 | -3 | 9 | 1 |
30 Sep 16 | 7 | -3 | 6 | 1 |
30 Jun 16 | 8 | -2 | 6 | 1 |
31 Mar 16 | 7 | -2 | 5 | 1 |
31 Dec 15 | 9 | 0 | 5 | 1 |
30 Sep 15 | 8 | -1 | 5 | 1 |
30 Jun 15 | 7 | -1 | 4 | 1 |
31 Mar 15 | 6 | -1 | 4 | 0 |
31 Dec 14 | 6 | -1 | 4 | 0 |
30 Sep 14 | 9 | 2 | 4 | 0 |
30 Jun 14 | 9 | 3 | 3 | 0 |
31 Mar 14 | 10 | 4 | 3 | 0 |
31 Dec 13 | 8 | 3 | 3 | 0 |
30 Sep 13 | 4 | -1 | 3 | 0 |
30 Jun 13 | 4 | -3 | 4 | 0 |
Quality Earnings: COV is currently unprofitable.
Growing Profit Margin: COV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COV is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.
Accelerating Growth: Unable to compare COV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: COV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: COV has a negative Return on Equity (-27.91%), as it is currently unprofitable.